Compare BMEA & PUSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BMEA | PUSA |
|---|---|---|
| Founded | 2017 | 2023 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 92.1M | 101.2M |
| IPO Year | 2021 | 2024 |
| Metric | BMEA | PUSA |
|---|---|---|
| Price | $1.37 | $2.53 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | ★ 1.7M | 902.3K |
| Earning Date | 11-03-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.19 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $2,964,377.00 |
| Revenue This Year | N/A | $1,620.43 |
| Revenue Next Year | N/A | $140.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.87 | $2.34 |
| 52 Week High | $2.24 | $4.45 |
| Indicator | BMEA | PUSA |
|---|---|---|
| Relative Strength Index (RSI) | 41.72 | 28.33 |
| Support Level | $1.15 | N/A |
| Resistance Level | $1.47 | $4.05 |
| Average True Range (ATR) | 0.12 | 0.33 |
| MACD | -0.03 | -0.13 |
| Stochastic Oscillator | 18.31 | 11.78 |
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.
Aureus Greenway Holdings Inc own and operate two public golf country clubs in Florida. The golf country clubs include two golf-courses with over 13,000 yards of combined fairways, clubhouses boasting food and beverage options, aquatic golf ranges, and pro shops to assist any level of golfer and also host local golf leagues, golf-tournaments, and private events. Its golf country clubs is organized into four principal business segments: (i) golf recreation, retail golf products, and equipment and facilities rental, (ii) membership dues, (iii) food and beverage services. and (iv) ancillary services and amenities. All assets of the Company are located in Florida and all revenue is generated from Florida.